News in Brief
MaSTherCell to make TCR candidates for Zelluna
Norwegian biopharma firm Zelluna has a number of cancer candidates in early and late stage pre-clinical development, based on its isolated and engineered TCRs.
And to bring these into the clinic, the firm has partnered with Orgenesis subsidiary MaSTherCell S.A. to perform process development, optimisation and industrialisation of the current manufacturing process.
“Manufacturing and providing process industrialization from the preclinical ground-level offers significant upside potential for us as the TCR products advance into further stages of clinical development, which Zelluna plans to commence in the 2019,” Orgenesis CEO Vered Caplan said in a statement.
Orgenesis bought MaSTherCell and its manufacturing facility in Gosselies, Belgium in 2015 to take control of production of its Type 1 diabetes cell therapy candidate ahead of clinical trials.
